Trey Ideker

Trey Ideker

Auto-generated profile, based on publicly available information

Trey Ideker

Program in Bioinformatics and Systems Biology, University of California, San Diego, La Jolla, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Molecular Cell
Verified
Journal Article
Closed access
GHGregory Hannum
Gregory Hannum
JGJustin Guinney
Justin Guinney
LZLing Zhao
Ling Zhao
LZLi Zhang
Li Zhang
GHGuy Hughes
Guy Hughes
KZKang Zhang
Kang Zhang

30 April 2020 in Nature
Verified
Journal Article
Closed access
PDF file
DGDavid E. Gordon
David E. Gordon
GJGwendolyn M. Jang
Gwendolyn M. Jang
MBMehdi Bouhaddou
Mehdi Bouhaddou
JXJiewei Xu
Jiewei Xu
KOKirsten Obernier
Kirsten Obernier
NKNevan J. Krogan
Nevan J. Krogan

6 November 2012 in Nature Methods
Verified
Journal Article
Closed access
PDF file
RSRintaro Saito
Rintaro Saito
MSMichael E Smoot
Michael E Smoot
KOKeiichiro Ono
Keiichiro Ono
JRJohannes Ruscheinski
Johannes Ruscheinski
PWPeng-Liang Wang
Peng-Liang Wang
TITrey Ideker
Trey Ideker

15 September 2013 in Nature Methods
Verified
Journal Article
Open access
PDF file
MHMatan Hofree
Matan Hofree
JSJohn P Shen
John P Shen
HCHannah Carter
Hannah Carter
AGAndrew Gross
Andrew Gross
TITrey Ideker
Trey Ideker
This paper reports a strategy for combining somatic mutation profiles of human tumors with gene networks to stratify tumors into biologically and clinically relevant subtypes. The method is applied to ovarian, uterine and lung cancers. Many forms of cancer have multiple subtypes with different causes and clinical outcomes. Somatic tumor genome sequences provide a rich new source of data for uncovering these subtypes but have proven difficult to compare, as two tumors rarely share the same mutations. Here we introduce network-based stratification (NBS), a method to integrate somatic tumor genomes with gene networks. This approach allows for stratification of cancer into informative subtypes by clustering together patients with mutations in similar network regions. We demonstrate NBS in ovarian, uterine and lung cancer cohorts from The Cancer Genome Atlas. For each tissue, NBS identifies subtypes that are predictive of clinical outcomes such as patient survival, response to therapy or tumor histology. We identify network regions characteristic of each subtype and show how mutation-derived subtypes can be used to train an mRNA expression signature, which provides similar information in the absence of DNA sequence.

17 January 2012 in Molecular Systems Biology
Verified
Journal Article
Open access
PDF file
TITrey Ideker
Trey Ideker
NKNevan J Krogan
Nevan J Krogan
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

4 December 2020 in Science
Verified
Journal Article
Open access
PDF file
DGDavid E. Gordon
David E. Gordon
JHJoseph Hiatt
Joseph Hiatt
MBMehdi Bouhaddou
Mehdi Bouhaddou
VRVeronica V. Rezelj
Veronica V. Rezelj
SUSvenja Ulferts
Svenja Ulferts
HLHarris A. Lewin
Harris A. Lewin
How lethal coronaviruses engage hosts: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is closely related to the deadly coronaviruses SARS-CoV-1 and Middle East respiratory syndrome coronavirus (MERS-CoV). Considerable efforts are focused on developing treatments, and therapies that work across coronaviruses would be particularly valuable. Shedding light on the host factors hijacked by the viruses, Gordon et al. mapped the interactions between viral and human proteins for SARS-CoV-2, SARS-CoV-1, and MERS-CoV; analyzed the localization of viral proteins in human cells; and used genetic screening to identify host factors that either enhance or inhibit viral infection. For a subset of the interactions essential for the virus life cycle, the authors determined the cryo–electron microscopy structures and mined patient data to understand how targeting host factors may be relevant to clinical outcomes. Science , this issue p. eabe9403